Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism

Sustained elevation of parathyroid hormone (PTH) is catabolic to cortical bone, as evidenced by deterioration in bone structure (cortical porosity), and is a major factor for increased fracture risk in chronic kidney disease (CKD). Etelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces PTH levels in subtotal nephrectomized (Nx) rats and in hemodialysis patients with secondary hyperparathyroidism (SHPT) in clinical studies; however, effects of etelcalcetide on bone have not been determined.

Source: Bone - September 1, 2017 Category: Orthopaedics Authors: Xiaodong Li, Longchuan Yu, Frank Asuncion, Mario Grisanti, Shawn Alexander, Kelly Hensley, Chun-Ya Han, Qing-Tian Niu, Denise Dwyer, Kelly Villasenor, Marina Stolina, Charles Dean, Michael S. Ominsky, Hua Zhu Ke, James E. Tomlinson, William G. Richards Source Type: research